Artificial intelligence as a mechanistic microscope and digital twin in colorectal cancer faces generalizability and regulatory validation limitations

Photo by Dmytro Vynohradov / Unsplash

Frontiers in Medicine Published June 7, 2026 Medically reviewed June 7, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that AI mechanistic microscopes and digital twins in colorectal cancer face generalizability and regulatory validation limitations.

This narrative review explores the potential application of artificial intelligence as a mechanistic microscope and digital twin within the context of colorectal cancer. The scope of the discussion centers on these emerging technologies rather than specific trial data or comparative outcomes. The authors do not report a sample size, setting, or specific adverse events for these interventions. Instead, the text focuses on the conceptual framework of using AI to model disease mechanisms and patient physiology.

The authors explicitly identify several critical barriers to clinical adoption. These include challenges related to generalizability, interpretability, and regulatory validation. Because the review does not report primary or secondary outcomes, the magnitude of any potential benefit cannot be quantified. The absence of reported safety data further limits the ability to assess tolerability or serious adverse events in this population.

Given the current state of evidence, the practice relevance of these technologies is not clearly defined. Clinicians should approach these concepts with caution until further data on efficacy and safety become available. The review serves to highlight the theoretical potential while acknowledging the substantial hurdles that must be overcome before these tools can be integrated into standard care for colorectal cancer patients.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

Colorectal cancer (CRC) remains a major cause of cancer-related death, yet the benefits of immune checkpoint inhibitors are limited to a small subset of patients, particularly those with microsatellite instability-high or mismatch repair-deficient tumors. Most patients with microsatellite-stable disease derive little benefit, and even responsive subgroups show substantial heterogeneity and acquired resistance. These challenges highlight the need for biomarkers and therapeutic frameworks that can not only predict response, but also explain underlying biology and support dynamic treatment decisions. In this review, we propose that artificial intelligence (AI) can move beyond prediction to serve two broader roles in CRC immunotherapy: as a mechanistic microscope that reveals hidden tumor–immune interactions from multimodal data, and as a digital twin that models patient-specific therapeutic trajectories over time. We summarize recent advances in AI-based pathology, imaging, and liquid biopsy for pretreatment stratification and response monitoring, and discuss how these approaches may inform resistance mapping, adaptive trial design, and strategies to convert immunologically “cold” tumors into “hot” tumors. We further examine key translational barriers, including generalizability, interpretability, and regulatory validation. By integrating multimodal data with mechanistic modeling, AI may help shift CRC immunotherapy from population-level prediction toward dynamic, individualized precision oncology.